1. Pink Sheet
  2. >>Legislation

FDA Appropriators Discuss Ending The Food & Drug Administration

 
• By Cathy Dombrowski

Splitting food authorities out of FDA suggested by Wyoming Republican Cynthia Lummis as the House Appropriations Agriculture/FDA subcommittee queries FDA Commissioner Margaret Hamburg on FY 2013 funding.

Food safety predominated at the first congressional review of the administration’s fiscal 2013 FDA budget proposal Feb. 29, prompting members of the House Appropriations Agriculture/FDA Subcommittee to revisit two issues that have failed to pass in previous Congresses – removal of food safety from the FDA agenda and food facility registration fees.

Republicans raised the issues as the panel questioned FDA Commissioner Margaret Hamburg about the $4.5 billion budget request, whose funding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.